4194 Stock Overview
Holy Stone Healthcare Co., Ltd. engages in the development of therapeutics in Taiwan.
Holy Stone Healthcare Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$19.40|
|52 Week High||NT$33.15|
|52 Week Low||NT$15.25|
|1 Month Change||-15.10%|
|3 Month Change||-26.93%|
|1 Year Change||8.99%|
|3 Year Change||45.21%|
|5 Year Change||14.12%|
|Change since IPO||-78.80%|
Recent News & Updates
If You Had Bought Holy Stone Healthcare (GTSM:4194) Shares A Year Ago You'd Have Earned 108% Returns
The last three months have been tough on Holy Stone Healthcare Co., Ltd. ( GTSM:4194 ) shareholders, who have seen the...
Holy Stone Healthcare (GTSM:4194) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. Indeed, Holy Stone Healthcare...
|4194||TW Biotechs||TW Market|
Return vs Industry: 4194 matched the TW Biotechs industry which returned 9.1% over the past year.
Return vs Market: 4194 exceeded the TW Market which returned 0.7% over the past year.
|4194 Average Weekly Movement||5.6%|
|Biotechs Industry Average Movement||5.3%|
|Market Average Movement||4.6%|
|10% most volatile stocks in TW Market||8.3%|
|10% least volatile stocks in TW Market||2.1%|
Stable Share Price: 4194 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 4194's weekly volatility (6%) has been stable over the past year.
About the Company
Holy Stone Healthcare Co., Ltd. engages in the development of therapeutics in Taiwan. It offers RenehaVis, a product designed to relive pain and stiffness of the knee joint; SportVis, a treatment to relive the pain and optimize the recovery of tendon and ligament injuries; TRUD, a treatment that allows mucosal tissue to heal naturally and reduces the symptoms of ulcerative colitis; and GAF, a treatment for anal mucosal lesions. The company is also developing IBD98-M, which is in Phase IIa clinical trials for the treatment of inflammatory bowel diseases; and CA102N to treat colorectal cancer.
Holy Stone Healthcare Fundamentals Summary
|4194 fundamental statistics|
Is 4194 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|4194 income statement (TTM)|
|Cost of Revenue||NT$115.26m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.31|
|Net Profit Margin||-83.52%|
How did 4194 perform over the long term?See historical performance and comparison
Is Holy Stone Healthcare undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 4194's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 4194's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: 4194 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.
PE vs Market: 4194 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4194's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4194 is overvalued based on its PB Ratio (10.2x) compared to the TW Biotechs industry average (3.8x).
How is Holy Stone Healthcare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Holy Stone Healthcare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Holy Stone Healthcare performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4194 is currently unprofitable.
Growing Profit Margin: 4194 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 4194 is unprofitable, but has reduced losses over the past 5 years at a rate of 6% per year.
Accelerating Growth: Unable to compare 4194's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4194 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).
Return on Equity
High ROE: 4194 has a negative Return on Equity (-68.66%), as it is currently unprofitable.
How is Holy Stone Healthcare's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 4194's short term assets (NT$248.6M) exceed its short term liabilities (NT$59.9M).
Long Term Liabilities: 4194's short term assets (NT$248.6M) exceed its long term liabilities (NT$18.6M).
Debt to Equity History and Analysis
Debt Level: 4194 is debt free.
Reducing Debt: 4194 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4194 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4194 has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 5.9% each year.
What is Holy Stone Healthcare current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 4194's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 4194's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 4194's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 4194's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 4194 has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Albert Wu is Chief Executive Officer of Holy Stone Healthcare Co., Ltd.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13%.
Holy Stone Healthcare Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Holy Stone Healthcare Co., Ltd.
- Ticker: 4194
- Exchange: TPEX
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: NT$2.692b
- Shares outstanding: 138.74m
- Website: https://www.hshc.com.tw
- Holy Stone Healthcare Co., Ltd.
- No. 88, Neihu Road
- 4th Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.